MTCR

NASDAQ

Metacrine Inc.

SectorHealth CareIndustry Medicinal Chemicals and Botanical Products IPO2020

News25/Ratings4

Metacrine, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with liver and gastrointestinal diseases. It is developing MET409 that has completed Phase 1b proof-of-concept clinical trial for the treatment of patients with non-alcoholic steatohepatitis (NASH); and is in Phase 2a clinical trial in combination with empagliflozin for the treatment of patients with type 2 diabetes mellitus and NASH. The company also develops MET642, which is in Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis patients. Metacrine, Inc. was incorporated in 2014 and is headquartered in San Diego, California.

Latest news

25 items

1126dSEC
SEC Form 15-12G filed by Metacrine Inc.
15-12G - Metacrine, Inc. (0001634379) (Filer)
1126dSEC
Metacrine Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Leadership Update, Submission of Matters to a Vote of Security Holders
8-K - Metacrine, Inc. (0001634379) (Filer)
1126dINSIDER
SEC Form 4 filed by Klassen Preston
4 - Metacrine, Inc. (0001634379) (Issuer)
1127dSEC
SEC Form S-8 POS filed by Metacrine Inc.
S-8 POS - Metacrine, Inc. (0001634379) (Filer)
1127dSEC
SEC Form S-8 POS filed by Metacrine Inc.
S-8 POS - Metacrine, Inc. (0001634379) (Filer)
1127dSEC
Metacrine Inc. filed SEC Form 8-K: Leadership Update
8-K - Metacrine, Inc. (0001634379) (Filer)
1135dSEC
Metacrine Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets
8-K - Metacrine, Inc. (0001634379) (Filer)
1143dSEC
SEC Form EFFECT filed by Metacrine Inc.
EFFECT - Metacrine, Inc. (0001634379) (Filer)
1147dSEC
SEC Form 25-NSE filed by Metacrine Inc.
25-NSE - Metacrine, Inc. (0001634379) (Subject)
1164d13D/G
SEC Form SC 13G/A filed by Metacrine Inc. (Amendment)
SC 13G/A - Metacrine, Inc. (0001634379) (Subject)
1165dSEC
SEC Form DEF 14A filed by Metacrine Inc.
DEF 14A - Metacrine, Inc. (0001634379) (Filer)
1169dSEC
Metacrine Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Events That Accelerate or Increase a Direct Financial Obligation
8-K - Metacrine, Inc. (0001634379) (Filer)
1170d13D/G
SEC Form SC 13G/A filed by Metacrine Inc. (Amendment)
SC 13G/A - Metacrine, Inc. (0001634379) (Subject)
1175dSEC
Metacrine Inc. filed SEC Form 8-K: Leadership Update
8-K - Metacrine, Inc. (0001634379) (Filer)
1177dNEWS
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers HTG Molecular Diagnostics (NASDAQ:HTGM) shares moved upwards by 33.0% to $6.01 during Wednesday's after-market session. This security traded at a volume of 323.6K shares come close, making up 21.6% of its average volume over the last 100 days. The company's market cap stands at $6.1 million. Lannett (NYSE:LCI) shares rose 15.74% to $0.62. The market value of their outstanding shares is at $26.2 million. As per the press release, Q2 earnings came out today. Align Tech (NASDAQ:ALGN) shares rose 15.03% to $325.0. At the close, Align Tech's trading volume reached 121.5K shares. This is 11.8% of its average volume over the last 100 days. The company's market cap stands at $25.3 billion
1177dSEC
Metacrine Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
8-K - Metacrine, Inc. (0001634379) (Filer)
1182dINSIDER
SEC Form 4: York Michael sold $44,331 worth of shares (107,054 units at $0.41), decreasing direct ownership by 51% to 103,499 units (tax withholding)
4 - Metacrine, Inc. (0001634379) (Issuer)
1182dINSIDER
SEC Form 4: Klassen Preston sold $157,266 worth of shares (380,605 units at $0.41), decreasing direct ownership by 41% to 541,905 units (tax withholding)
4 - Metacrine, Inc. (0001634379) (Issuer)
1185dNEWS
Metacrine Says President, CEO, Secretary, Principal Executive Officer Preston Klassen Was Terminated From Positions, Effective Feb. 1
-Reuters
1185dSEC
SEC Form PRE 14A filed by Metacrine Inc.
PRE 14A - Metacrine, Inc. (0001634379) (Filer)
1185dSEC
Metacrine Inc. filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits
8-K - Metacrine, Inc. (0001634379) (Filer)
1213dNEWS
Metacrine, Equillium And 3 Stocks To Watch Heading Into Tuesday
With US stock futures trading higher this morning on Friday, some of the stocks that may grab investor focus today are as follows: Metacrine, Inc. (NASDAQ:MTCR) and Equillium, Inc. (NASDAQ:EQ) mutually agreed to terminate definitive merger agreement. Metacrine shares jumped 5.4% to $0.4551 in after-hours trading, while Equillium shares dropped 6.3% to close at $0.89 on Friday. Oragenics, Inc. (NYSE:OGEN) disclosed a 1-for-60 reverse stock split. Oragenics shares dipped 6.7% to close at $0.1450 on Friday. Check out our premarket coverage here Pintec Technology Holdings Limited (NASDAQ:PT) reported that its total revenues dropped by 56.53% year-over-year to RMB39.82 million ($5.93 mi
1217dNEWS
Metacrine Shares Resume Trade Following Circuit Breaker Halt, Stock Now Up 14%
1217dSEC
Metacrine Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits
8-K - Metacrine, Inc. (0001634379) (Filer)
1217dNEWS
Metacrine and Equillium Mutually Agree to Terminate Definitive Merger Agreement
Metacrine, Inc. (NASDAQ:MTCR) and Equillium, Inc. today announced the mutual termination of their previously announced definitive merger agreement. Metacrine is continuing to evaluate all strategic opportunities. Additional information regarding the termination of the definitive merger agreement is provided set forth in a Current Report on Form 8-K filed by Metacrine with the U.S. Securities and Exchange Commission today and is available at www.sec.gov and on Metacrine's website under the heading "Investors."